Viral Vectors and Plasmid DNA Manufacturing Market Size

Ottawa, Aug. 21, 2025 (GLOBE NEWSWIRE) — The global market for viral vectors and plasmid DNA manufacturing reached USD 6.26 billion in 2024 and is projected to grow from USD 7.26 billion in 2025 to approximately USD 26.66 billion by 2034. The market is expected to expand at a compound annual growth rate (CAGR) of 15.59% from 2025 to 2034, driven primarily by increasing demand for gene therapies, vaccines, and cell-based treatments.

North America held the largest market share at 49% in 2024, with significant contributions from various sectors, including research institutes and biopharmaceutical companies. The adeno-associated virus (AAV) segment contributed the highest market share by vector type, while the vaccinology application segment accounted for the largest share by application.

Key factors contributing to this growth include advancements in manufacturing technologies such as automation and single-use bioreactors, as well as the rising prevalence of genetic disorders and cancers. However, regulatory compliance remains a significant challenge in ensuring the safety and effectiveness of products.

In summary, the viral vectors and plasmid DNA manufacturing market reflects a substantial opportunity for stakeholders as the landscape shifts towards more sophisticated therapies.

• Why it matters:
  • The growing market indicates opportunities for investment in gene therapy and vaccine development.
  • Companies in biopharmaceuticals may leverage this growth for strategic partnerships and advancements in product pipelines.
• The latest: In August 2025, Probio launched a new plasmid DNA and viral vector manufacturing facility in the U.S. to support gene and cell therapy developers.